Takeda’s Diabetes Drug Found At Increased Risk Of Bone Fractures
This article was originally published in PharmAsia News
Executive Summary
Takeda Phamaceuticals' diabetes drug Actos (pioglitazone) has come under fire along with another major drug for being linked to a higher risk of bone fractures. A review of medical data has shown Takeda's drug and GlaxoSmithKline's Avandia (rosiglitazone), also for diabetes, may increase the risk by 43 percent. Although Avandia already had been linked to fractures, the new study showed patients taking Actos were equally at risk of broken bones. Both drugs are in the TZD drug class and together they have about four million customers in the U.S. The study was conducted by Medco Health Solutions and the University Of Texas. (Click here for more - a subscription may be required